Yeda Research and Development Co. Ltd.
31 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 25 name spellings.
32
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 6 fees due Dec 2 to 30, 2026 · next Dec 2
- 2 fees due Jan 2 to 23, 2027 · next Jan 2
- 5 fees due Feb 6 to 22, 2027 · next Feb 6
- 3 fees due Mar 5 to 19, 2027 · next Mar 5
- 10 fees due Apr 1 to 29, 2027 · next Apr 1
- 4 fees due May 3 to 19, 2027 · next May 3
- 9 fees due Jun 5 to 30, 2027 · next Jun 5
- 8 fees due Jul 7 to 30, 2027 · next Jul 7
- 10 fees due Aug 4 to 20, 2027 · next Aug 4
- 5 fees due Sep 5 to 22, 2027 · next Sep 5
- 8 fees due Oct 2 to 23, 2027 · next Oct 2
- 2 fees due Nov 7 to 14, 2027 · next Nov 7
Recent changes
- 12 of the patents on this record were granted since Aug 18, 2026
- 6 terms have ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,388,954 | Stabilising Formulation for Immunoglobulin G Compositions in Liquid Form and in Lyophilised Form In force · High confidence | In force | High confidence | |
| US 10,258,651 | Methods of Generating Glial and Neuronal Cells and Use of Same for the Treatment of Medical Conditions of the CNS In force · High confidence | In force | High confidence | |
| US 11,406,670 | Methods of Generating Glial and Neuronal Cells and Use of Same for the Treatment of Medical Conditions of the CNS In force · High confidence | In force | High confidence | |
| US 9,957,293 | Conjugates of RGD peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses In force · From the USPTO record | In force | From the USPTO record | |
| US 10,689,415 | Conjugates of RGD Peptides and (BACTERIO)CHLOROPHYLL Photosensitizers In force · Medium confidence | In force | Medium confidence | |
| US 7,947,672 | Water-Soluble Anionic Bacteriochlorophyll Derivatives and Their Uses In force · Medium confidence | In force | Medium confidence | |
| US 8,067,008 | Peptide Inhibitors for Mediating Stress Responses In force · High confidence | In force | High confidence | |
| US 9,631,175 | Methods of Generating Glial and Neuronal Cells and Use of Same for the Treatment of Medical Conditions of the CNS In force · High confidence | In force | High confidence | |
| US 11,326,147 | Redirected, Genetically-Engineered T Regulatory Cells and Their Use in Suppression of Autoimmune and Inflammatory Disease In force · High confidence | In force | High confidence | |
| US 8,486,653 | Antibodies and Pharmaceutical Compositions Containing Same Useful for Inhibiting Activity of Metalloproteins In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 284: 31 patents in force now held by others · 428 lapsed for an unpaid fee · 546 ended at full term · 1 past the fee grace period · 2 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
125 pending · 365 abandoned · 55 no status recorded